IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a report published on Thursday. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Up 0.7 %

IRIX opened at $1.51 on Thursday. The firm has a market cap of $25.13 million, a price-to-earnings ratio of -2.25 and a beta of 0.84. IRIDEX has a 52 week low of $1.27 and a 52 week high of $3.65. The business’s 50 day moving average is $1.68 and its two-hundred day moving average is $1.74. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The firm had revenue of $11.58 million for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same quarter last year, the business posted ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.